| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences, Inc. (GILD) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 16 sells. GILD is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 626.3K | $78.14M | -15,000 | |
| Other | 46.9K | $5.85M | - | |
| Other | 46.6K | $5.81M | - | |
| VP | 44.2K | $5.51M | - | |
| Other | 27.9K | $3.47M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 23, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $75.02 | $437,587.58 | -10.0% | |
| Mar 16, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $80.09 | $467,137.55 | -10.0% | |
| Mar 12, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $80.93 | $472,064.69 | -10.0% | |
| Mar 1, 2018 | Martin John C | Executive Chairman | Sale+OE | 50,000 | $78.65 | $3,932,375.01 | -0.5% | |
| Mar 1, 2018 | Alton Gregg H | EVP,Corporate &Medical Affairs | Sale+OE | 25,000 | $78.69 | $1,967,314.57 | -13.8% | |
| Feb 28, 2018 | Washington Robin L | EVP, CFO | Sell | 5,000 | $80.31 | $401,566.00 | -4.5% | |
| Feb 20, 2018 | Alton Gregg H | EVP,Corporate &Medical Affairs | Sell | 14,435 | $81.54 | $1,176,992.37 | -100% | |
| Feb 9, 2018 | Wilson Gayle E | Director | Sale+OE | 60,000 | $77.92 | $4,675,080.00 | -32.9% | |
| Feb 1, 2018 | Alton Gregg H | EVP,Corporate &Medical Affairs | Sale+OE | 25,000 | $83.51 | $2,087,860.15 | -21.6% | |
| Feb 1, 2018 | Martin John C | Executive Chairman | Sale+OE | 50,000 | $83.56 | $4,177,824.31 | -0.8% |